Compare Arm Holdings plc (ARM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs Incyte Corporation — how do they compare? Arm Holdings plc trades at $274.08 (market cap $287.22B), while Incyte Corporation trades at $120.77 (market cap $24.54B). The key difference: Arm Holdings plc is far larger — about 11.7× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | INCY | |
|---|---|---|
Market Cap | $287.22B | $24.54B |
Sector | Technology | Health |
52-Week High | $439.46 | $129.93 |
52-Week Low | $104.55 | $81.66 |
Enterprise Value | $283.79B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM stock trades at $271.87, up 1.5% in the last 24 hours, with a bullish technical signal and strong quarterly earnings beats. The company reported robust revenue growth, reaching $4.01 billion in 2025, with a net income margin of 20.25%. Recent news highlights AI-driven optimism, though valuation metrics like a P/E of 274.42 indicate premium pricing.
Outlook is positive with analyst consensus favoring a buy rating (70.37%) and a $329.80 price target, but risks include high valuation sensitivity and competitive pressures in the smartphone market. Earnings growth from AI and data center demand presents opportunity, yet investors must weigh stretched multiples against execution risks.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
